A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Ocular Myasthenia Gravis
Interventions
DRUG:
Rozanolixizumab
Sponsor
UCB Biopharma SRL